Theragenics Corporation(R) Sets Annual Meeting Date.BUFORD, Ga. -- Theragenics Corporation(R) (NYSE NYSE See: New York Stock Exchange : TGX TGX Theragenics Corporation (stock symbol) TGX Trajectory Generator External ), a medical device company serving the cancer treatment and surgical markets, today announced its Annual Meeting of the Stockholders will be held on Tuesday, May 9, 2006, at 9:00 a.m., Eastern Time, at The Ritz-Carlton Atlanta (Downtown), 181 Peachtree Street, N.E., Atlanta, GA 30303. The purpose of the meeting is to consider the election of one Director, the adoption of Theragenics Corporation's 2006 Stock Incentive Plan, the ratification of the appointment of Grant Thornton LLP Please help [ rewrite this article] from a neutral point of view. Mark blatant advertising for , using . as independent auditor Independent Auditor An external auditor with a certified public accounting designation that qualifies him or her to provide an auditor's report. Notes: These auditors aren't affiliated with the company being audited. , and to transact any other business as may properly come before the meeting or any adjournment thereof. The Board of Directors fixed the close of business on March 10, 2006, as the record date for the determination of the stockholders entitled to notice of, and to vote at, the meeting. It is anticipated that the Proxy Statement Proxy Statement A document containing the information that a company is required by the SEC to provide to shareholders so they can make informed decisions about matters that will be brought up at an annual stockholder meeting. , Proxy and Annual Report will be mailed to the stockholders entitled to notice of and to vote at the Annual Meeting on or around March 31, 2006. This announcement serves to satisfy the public disclosure requirement of the Annual Meeting of the Stockholders as addressed in the by-laws of Theragenics Corporation. Theragenics Corporation(R) (NYSE: TGX) is a provider of brachytherapy and surgical products. In Buford, Ga., the Company manufactures and markets its premiere product, the palladium-103 TheraSeed(R) device (www.theraseed.com), and I-Seed, an iodine-125 based device, which are used primarily in the minimally invasive treatment of localized prostate cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. . Theragenics is the world's largest producer of palladium-103 for human use. Through its subsidiary, CP Medical (www.cpmedical.com), based in Portland, Ore., the Company manufactures and distributes medical products for diverse surgical markets including wound closure, cardiac pacing, and the general, dental, cosmetic and veterinary markets. For additional information, call the Company's Investor Relations Investor relations The process by which the corporation communicates with its investors. Department at (800) 998-8479 or visit www.theragenics.com. |
|
||||||||||||||||

Printer friendly
Cite/link
Email
Feedback
Reader Opinion